Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and Above With no Vaccination History of COVID-19 Vaccine

NCT05365724 is registered in ClinicalTrials.gov with China National Biotec Group Company Limited as lead sponsor.

NCT NCT05365724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05365724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and Above With no Vaccination History of COVID-19 Vaccine
Lead sponsor
China National Biotec Group Company Limited
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 1, 2022
Completion date
October 1, 2023
Enrollment
280 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19